

## Intended Use

For the quantitative determination of creatine kinase activity in serum.




## Clinical Significance

Creatine kinase (CK) is primarily found in skeletal muscle, cardiac muscle and brain tissue. Damage to any of these tissues may result in increased levels of CK activity in serum. Cardiac muscle damage following myocardial infarction usually results in an increase to 7-12 times the upper limit of normal within 18 to 30 hours of the infarction. Elevated CK activity is also noted in hypothyroidism, various types of muscular dystrophy, viral myositis and similar types of skeletal muscle disease.<sup>1</sup> The determination of serum CK activity is used to aid in the diagnosis of myocardial infarction and various types of muscle disease.

## Method History

The first procedure for determining CK, based on the rate of ATP formation, was presented by Oliver in 1955.<sup>2</sup> A modified method was described by Nielson and Ludvigsen<sup>3</sup> in 1963 with Rosalki<sup>4</sup> adding a sulfhydryl compound and AMP in 1967 to assure maximum CK activity and inhibit adenylate kinase activity. Optimized conditions for measuring CK were published by Szasz<sup>5</sup> in 1976 as well as by the Scandinavian Committee on Enzymes.<sup>6</sup> The above procedure was modified again in 1979<sup>7</sup> to include EDTA. The present reagent is a modification of the above revision.

## Principle



CK catalyzes the reversible phosphorylation of ADP, in the presence of creatine phosphate, to form ATP and creatine. The auxiliary enzyme hexokinase (HK) catalyzes the phosphorylation of glucose by the ATP formed, to produce ADP and glucose-6-phosphate (G<sub>6</sub>P). The G<sub>6</sub>P is oxidized to 6-phosphogluconate with the concomitant production of NADH. The rate of NADH formation, measured at 340nm, is directly proportional to serum CK activity.

## Reagents

(Concentrations refer to reconstituted reagent). Creatine Phosphate 30mM, ADP 2mM, AMP 5mM, NAD 2mM, NAC 20mM, Hexokinase (microbial) 2500 U/L, G<sub>6</sub>PDH (microbial) 2000 U/L, D-Glucose 20mM, Magnesium Ions 10mM, EDTA 2.0mM, Diadenosine Pentaphosphate 10uM, Buffer 100mM, pH 6.7±0.1, non-reactive stabilizers and fillers with sodium azide (0.05%) as preservative.

## Reagent Preparation

Reconstitute reagent with the volume of distilled water stated on the vial. Swirl to dissolve.

## Reagent Storage

1. Dry reagent should be stored at 2-8°C until the expiration date.
2. Reconstituted reagent is stable for twenty-four hours at room temperature (18-25°C) or 30 days at 2-8°C.

## Reagent Deterioration

Do not use if:

1. Moisture has entered the vial and caking has occurred.
2. The reconstituted reagent has an absorbance greater than 0.700 at 340nm against water.

## Precautions

1. This reagent is for *in vitro* diagnostic use only.
2. Reconstituted reagent may be irritating to skin. Flush skin with water if contacted.
3. This reagent contains sodium azide (0.05%) as a preservative. Do not ingest. May react with lead and copper plumbing to form highly explosive metal azides. Upon disposal, flush with a large volume of water to prevent azide build up.

## Specimen Collection and Storage

1. Serum is the specimen of choice. Rosalki has reported that plasma (Heparin or EDTA ) may be used.<sup>4</sup>
2. Red cells have very little CK, therefore slight hemolysis is acceptable.<sup>8,4</sup>
3. CK in serum is stable for forty-eight hours at room temperature (18-25°C) and seven days refrigerated (2-8°C). The sample may be frozen for up to one month when protected against evaporation.<sup>4</sup>
4. Strenuous exercise or physical activity can produce elevated levels of CK in serum.<sup>1</sup>

## Interferences

1. Certain drugs and medications may affect the activity of CK, see Young, et al.<sup>9</sup>
2. Elevated levels of bilirubin (20mg/dl) and hemoglobin (500mg/dl) have been found to have negligible effect on this assay.

## Materials Provided

CK reagent.

## Materials Required but not Provided

1. Accurate pipetting devices
2. Timer
3. Test tubes/rack
4. Spectrophotometer with the ability to read at 340nm
5. Heating Block (37°C)

## Procedure (Automated)

Refer to specific instrument application instructions.

## Procedure (Manual)

1. Reconstruct reagent according to instructions.
2. Pipette 1.0 ml of reagent into appropriate tubes and pre-warm at 37°C for five minutes.
3. Zero spectrophotometer with water at 340 nm.
4. Transfer 0.025ml(25ul) of sample to reagent, mix and incubate at 37°C for two minutes.
5. After two minutes, read and record the absorbance. Return tube to 37°C. Repeat readings every minute for the next two minutes.
6. Calculate the average absorbance difference per minute ( $\Delta\text{Abs./min.}$ ).
7. The  $\Delta\text{Abs./min.}$  multiplied by the factor 6592 (see Calculations) will yield results in U/L.

# Creatine Kinase (CK) Reagent Set

## Procedure Notes

1. Samples with values above 1500 U/L should be diluted 1:1 with saline, re-assayed and the results multiplied by two.
2. If the spectrophotometer being used is equipped with temperature controlled cuvette, the reaction mixture may be left in the cuvette while the absorbance readings are taken.

## Limitations

1. The present procedure measures total CK, regardless of its source.
2. Samples with values above 1500 U/L should be diluted 1:1 with saline, re-assayed and the results multiplied by two.

## Calibration<sup>10,11</sup>

The procedure is standardized by means of the millimolar absorptivity of NADH taken as 6.22 at 340nm under the described test conditions. Refer to the "Calculations" section for information on the calculation of the enzyme activity of the sample.

## Calculations

One international Unit (U/L) is defined as the amount of enzyme that catalyzes the transformation of one micromole of substrate per minute under defined conditions.

$$U/L = \frac{\Delta Abs./min. \times 1.025 \times 1000}{1 \times 6.22 \times .025} = \Delta Abs./min. \times 6592$$

Where:  $\Delta Abs./min.$  = Average absorbance change per minute  
1.025 = Total reaction volume  
1000 = Conversion of U/ml to U/L  
1 = Light path in cm  
6.22 = Millimolar absorptivity of NADH  
.025 = Sample volume in ml

Example: If your average absorbance change per minute is .01,  
then  $.01 \times 6592 = 66$  IU/L

Note: If any of the test parameters are changed, a new factor has to be determined using the above formula.

SI Units: To convert to SI Units (nkat/L) multiply U/L by 16.67.

## Quality Control

The validity of the reaction should be monitored by use of control sera with known normal and abnormal creatine kinase values. These controls should be run at least with every working shift in which creatine kinase assays are performed. It is recommended that each laboratory establish their own frequency of control determination.

## Expected Values<sup>12</sup>

The following values are based on measurements performed at 37°C:

Males: Up to 160 U/L

Females: Up to 130 U/L

Newborns: 2 to 3 times adult values.

It is strongly recommended that each laboratory establish its own reference range.

## Performance

1. Linearity: 1500 U/L
2. Comparison: Studies done between this procedure and a similar procedure yielded a correlation coefficient of 0.999 with a regression equation of  $y=1.07x-5.6$ . (n=103, range=25-2047 U/L)
3. Precision:

Within Run			Run to Run		
Mean	S.D.	C.V.%	Mean	S.D.	C.V.%
152	1.3	0.9	155	1.6	1.0
483	1.7	0.4	486	2.2	0.5

4. Sensitivity: Under the reaction conditions described, 1 U/L of creatine kinase gives a  $\Delta Abs./min.$  of 0.00015.

## References

1. Tietz, N.W., Fundamentals of Clinical Chemistry, Philadelphia, W.B. Saunders Co., pp. 682-689 (1982).
2. Oliver, I.T., Biochem. J. 61:116 (1955).
3. Nielson, L., Ludvigsen, B., J. Lab. Clin. Med. 62:159 (1963).
4. Rosalki, S.B., J. Lab. Clin. Med. 69:696 (1967).
5. Szasz, G., et al, Clin. Chem. 22:650 (1976).
6. The Committee on Enzymes of the Scandinavian Society for Clinical Chemistry and Clinical Physiology, Scand., J. Clin. Lab. Invest 36:711 (1976).
7. The Committee on Enzymes of the Scandinavian Society for Clinical Chemistry and Clinical Physiology, Scand. J. Clin. Lab. Invest 39:1 (1979).
8. Engle, W.K., Meitzer, H., Science 168:273 (1970).
9. Young, D.S. et al, Clin. Chem. 21:1D (1976).
10. Ziegenhorn, J., et al, Clin. Chem. 22:151 (1976).
11. McComb, R.B., et al, Clin. Chem. 22:141 (1976).
12. Kaplan, L.A., and Pesce, A.J., Clinical Chemistry: Theory, analysis, and correlation, St. Louis, C.V. Mosby Co., p. 921 (1989).

Manufactured by Pointe Scientific, Inc.  
5449 Research Drive Canton, MI 48188

"European Authorized Representative"  
(O.E.A.R.C.) Av. De Tervueren 34 bte  
44 B-1040 Brussels, Belgium



Rev. 5/03 P803-C7512-01